amodiaquine has been researched along with Recrudescence in 34 studies
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations." | 9.51 | Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022) |
| " The objective was to assess the efficacy and safety of repeated administrations of two fixed-dose presentations of ACT--artesunate plus amodiaquine (ASAQ) and artemether-lumefantrine (AL)--in subsequent episodes of Plasmodium falciparum malaria." | 9.15 | Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. ( Barry, A; Cissé, B; Faye, B; Gaye, O; Gueye, A; Lameyre, V; Ndiaye, D; Ndiaye, I; Ndiaye, JL; Tchania, C; Tine, R, 2011) |
| " In the present study, the efficacies of chloroquine (CQ) or amodiaquine (AQ) in the oral treatment of acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were compared with those of oral treatments with the combination of CQ or AQ with pyrimethamine-sulfadoxine (PS)." | 9.10 | A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2002) |
| "Twenty-eight day in-vivo efficacy trial of amodiaquine-artesunate in 103 children aged 6-59 months in western Kenya with smear-confirmed uncomplicated Plasmodium falciparum malaria." | 7.75 | In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. ( Desai, M; Hamel, MJ; Kariuki, S; McMorrow, M; Newman, RD; Odero, CO; Odhiambo, FO; Ord, R; Otieno, KO; Roper, C; Slutsker, L; Thwing, JI; Vulule, J, 2009) |
| " The findings indicate that - at least at the dosing regimen used in the present study and among children with acute, uncomplicated, P." | 6.71 | A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2003) |
| "AS-MQ and AL are more effective than DP and AS-AQ FDC in preventing gametocytaemia shortly after treatment, suggesting that the non-artemisinin partner drug or the timing of artemisinin dosing are important determinants of post-treatment gametocyte dynamics." | 6.53 | Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. ( , 2016) |
| "Artemether-lumefantrine plus amodiaquine provides an alternative to artemether-lumefantrine alone as first-line treatment for multidrug-resistant P falciparum malaria in the Greater Mekong subregion, and could prolong the therapeutic lifetime of artemether-lumefantrine in malaria-endemic populations." | 5.51 | Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. ( Amaratunga, C; Callery, JJ; Chau, NH; Chotivanich, K; Chotsiri, P; Day, NPJ; Dhorda, M; Dondorp, AM; Duanguppama, J; Dung, NTP; Hien, TT; Hoglund, RM; Imwong, M; Lek, D; Long, LT; Maude, RJ; Miotto, O; Mukaka, M; Nghia, HDT; Nguon, C; Peto, TJ; Rekol, H; Ruecker, A; Sokha, M; Sovann, Y; Tarning, J; Thuong, NTH; Tripura, R; van der Pluijm, RW; Van Luong, V; von Seidlein, L; Waithira, N; White, NJ, 2022) |
| " The objective was to assess the efficacy and safety of repeated administrations of two fixed-dose presentations of ACT--artesunate plus amodiaquine (ASAQ) and artemether-lumefantrine (AL)--in subsequent episodes of Plasmodium falciparum malaria." | 5.15 | Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. ( Barry, A; Cissé, B; Faye, B; Gaye, O; Gueye, A; Lameyre, V; Ndiaye, D; Ndiaye, I; Ndiaye, JL; Tchania, C; Tine, R, 2011) |
| " In the present study, the efficacies of chloroquine (CQ) or amodiaquine (AQ) in the oral treatment of acute, symptomatic, uncomplicated, Plasmodium falciparum malaria were compared with those of oral treatments with the combination of CQ or AQ with pyrimethamine-sulfadoxine (PS)." | 5.10 | A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2002) |
| "Artesunate-amodiaquine (AS-AQ) is one of the most widely used artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria in Africa." | 4.91 | The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. ( Adjuik, MA; Allan, R; Anvikar, AR; Ashley, EA; Ba, MS; Barennes, H; Barnes, KI; Bassat, Q; Baudin, E; Björkman, A; Bompart, F; Bonnet, M; Borrmann, S; Brasseur, P; Bukirwa, H; Checchi, F; Cot, M; D'Alessandro, U; Dahal, P; Deloron, P; Desai, M; Diap, G; Djimde, AA; Dorsey, G; Doumbo, OK; Espié, E; Etard, JF; Fanello, CI; Faucher, JF; Faye, B; Flegg, JA; Gaye, O; Gething, PW; González, R; Grandesso, F; Guerin, PJ; Guthmann, JP; Hamour, S; Hasugian, AR; Hay, SI; Humphreys, GS; Ibrahim, LM; Jullien, V; Juma, E; Kamya, MR; Karema, C; Kiechel, JR; Kremsner, PG; Krishna, S; Lameyre, V; Lee, SJ; Lell, B; Mårtensson, A; Massougbodji, A; Menan, H; Ménard, D; Menéndez, C; Meremikwu, M; Moreira, C; Nabasumba, C; Nambozi, M; Ndiaye, JL; Nikiema, F; Nsanzabana, C; Ntoumi, F; Ogutu, BR; Olliaro, P; Osorio, L; Ouédraogo, JB; Penali, LK; Pene, M; Pinoges, L; Piola, P; Price, RN; Roper, C; Rosenthal, PJ; Rwagacondo, CE; Same-Ekobo, A; Schramm, B; Seck, A; Sharma, B; Sibley, CH; Sinou, V; Sirima, SB; Smith, JJ; Smithuis, F; Somé, FA; Sow, D; Staedke, SG; Stepniewska, K; Swarthout, TD; Sylla, K; Talisuna, AO; Tarning, J; Taylor, WR; Temu, EA; Thwing, JI; Tine, RC; Tinto, H; Tjitra, E; Vaillant, MT; Valecha, N; Van den Broek, I; White, NJ; Yeka, A; Zongo, I, 2015) |
| "Twenty-eight day in-vivo efficacy trial of amodiaquine-artesunate in 103 children aged 6-59 months in western Kenya with smear-confirmed uncomplicated Plasmodium falciparum malaria." | 3.75 | In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. ( Desai, M; Hamel, MJ; Kariuki, S; McMorrow, M; Newman, RD; Odero, CO; Odhiambo, FO; Ord, R; Otieno, KO; Roper, C; Slutsker, L; Thwing, JI; Vulule, J, 2009) |
| " Follow-up visits were performed on days 3, 7, 14, 21, and 28 to evaluate clinical and parasitological resolution of their malaria episode as well as adverse events." | 2.80 | Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. ( Derra, K; Diallo-Nakanabo, S; Guiguemde, TR; Kazienga, A; Ouedraogo, JB; Owusu-Dabo, E; Sondo, P; Sorgho, H; Tarnagda, Z; Tinto, H; Valea, I; Zampa, O, 2015) |
| "Nearly all recurrences were due to new infections." | 2.73 | Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. ( Dokomajilar, C; Dorsey, G; Guiguemde, RT; Ouedraogo, JB; Rosenthal, PJ; Rouamba, N; Tinto, H; Zongo, I, 2007) |
| " The findings indicate that - at least at the dosing regimen used in the present study and among children with acute, uncomplicated, P." | 2.71 | A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Sowunmi, A, 2003) |
| "AS-MQ and AL are more effective than DP and AS-AQ FDC in preventing gametocytaemia shortly after treatment, suggesting that the non-artemisinin partner drug or the timing of artemisinin dosing are important determinants of post-treatment gametocyte dynamics." | 2.53 | Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. ( , 2016) |
| "Recrudescence was detected by a thick blood smear and confirmed by polymerase chain reaction." | 1.35 | Some features of primary and recrudescent amodiaquine-resistant Plasmodium falciparum infections in Nigerian children. ( Balogun, ST; Gbotosho, GO; Happi, CT; Sowunmi, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (17.65) | 18.7374 |
| 1990's | 3 (8.82) | 18.2507 |
| 2000's | 11 (32.35) | 29.6817 |
| 2010's | 12 (35.29) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Dentinger, CM | 1 |
| Rakotomanga, TA | 1 |
| Rakotondrandriana, A | 1 |
| Rakotoarisoa, A | 1 |
| Rason, MA | 1 |
| Moriarty, LF | 1 |
| Steinhardt, LC | 1 |
| Kapesa, L | 1 |
| Razafindrakoto, J | 1 |
| Svigel, SS | 1 |
| Lucchi, NW | 1 |
| Udhayakumar, V | 2 |
| Halsey, ES | 2 |
| Ratsimbasoa, CA | 1 |
| Peto, TJ | 1 |
| Tripura, R | 1 |
| Callery, JJ | 1 |
| Lek, D | 1 |
| Nghia, HDT | 1 |
| Nguon, C | 1 |
| Thuong, NTH | 1 |
| van der Pluijm, RW | 1 |
| Dung, NTP | 1 |
| Sokha, M | 1 |
| Van Luong, V | 1 |
| Long, LT | 1 |
| Sovann, Y | 1 |
| Duanguppama, J | 1 |
| Waithira, N | 1 |
| Hoglund, RM | 1 |
| Chotsiri, P | 1 |
| Chau, NH | 1 |
| Ruecker, A | 1 |
| Amaratunga, C | 1 |
| Dhorda, M | 1 |
| Miotto, O | 1 |
| Maude, RJ | 1 |
| Rekol, H | 1 |
| Chotivanich, K | 1 |
| Tarning, J | 2 |
| von Seidlein, L | 1 |
| Imwong, M | 1 |
| Mukaka, M | 1 |
| Day, NPJ | 1 |
| Hien, TT | 1 |
| White, NJ | 2 |
| Dondorp, AM | 1 |
| Andrianaranjaka, V | 1 |
| Lin, JT | 1 |
| Golden, C | 1 |
| Juliano, JJ | 1 |
| Randrianarivelojosia, M | 1 |
| Muhindo Mavoko, H | 1 |
| Nabasumba, C | 2 |
| Tinto, H | 4 |
| D'Alessandro, U | 2 |
| Grobusch, MP | 1 |
| Lutumba, P | 1 |
| Van Geertruyden, JP | 1 |
| Adjuik, MA | 1 |
| Allan, R | 1 |
| Anvikar, AR | 1 |
| Ashley, EA | 1 |
| Ba, MS | 1 |
| Barennes, H | 1 |
| Barnes, KI | 1 |
| Bassat, Q | 1 |
| Baudin, E | 1 |
| Björkman, A | 2 |
| Bompart, F | 1 |
| Bonnet, M | 1 |
| Borrmann, S | 1 |
| Brasseur, P | 1 |
| Bukirwa, H | 1 |
| Checchi, F | 1 |
| Cot, M | 1 |
| Dahal, P | 1 |
| Deloron, P | 2 |
| Desai, M | 2 |
| Diap, G | 1 |
| Djimde, AA | 1 |
| Dorsey, G | 4 |
| Doumbo, OK | 1 |
| Espié, E | 1 |
| Etard, JF | 1 |
| Fanello, CI | 1 |
| Faucher, JF | 1 |
| Faye, B | 2 |
| Flegg, JA | 1 |
| Gaye, O | 2 |
| Gething, PW | 1 |
| González, R | 1 |
| Grandesso, F | 1 |
| Guerin, PJ | 1 |
| Guthmann, JP | 1 |
| Hamour, S | 1 |
| Hasugian, AR | 2 |
| Hay, SI | 1 |
| Humphreys, GS | 1 |
| Jullien, V | 1 |
| Juma, E | 1 |
| Kamya, MR | 1 |
| Karema, C | 1 |
| Kiechel, JR | 1 |
| Kremsner, PG | 1 |
| Krishna, S | 1 |
| Lameyre, V | 3 |
| Ibrahim, LM | 1 |
| Lee, SJ | 1 |
| Lell, B | 1 |
| Mårtensson, A | 1 |
| Massougbodji, A | 1 |
| Menan, H | 1 |
| Ménard, D | 1 |
| Menéndez, C | 1 |
| Meremikwu, M | 1 |
| Moreira, C | 1 |
| Nambozi, M | 1 |
| Ndiaye, JL | 2 |
| Nikiema, F | 1 |
| Nsanzabana, C | 1 |
| Ntoumi, F | 2 |
| Ogutu, BR | 1 |
| Olliaro, P | 1 |
| Osorio, L | 1 |
| Ouédraogo, JB | 5 |
| Penali, LK | 1 |
| Pene, M | 1 |
| Pinoges, L | 1 |
| Piola, P | 1 |
| Price, RN | 2 |
| Roper, C | 2 |
| Rosenthal, PJ | 5 |
| Rwagacondo, CE | 1 |
| Same-Ekobo, A | 1 |
| Schramm, B | 1 |
| Seck, A | 1 |
| Sharma, B | 1 |
| Sibley, CH | 1 |
| Sinou, V | 1 |
| Sirima, SB | 1 |
| Smith, JJ | 1 |
| Smithuis, F | 1 |
| Somé, FA | 1 |
| Sow, D | 1 |
| Staedke, SG | 1 |
| Stepniewska, K | 1 |
| Swarthout, TD | 1 |
| Sylla, K | 1 |
| Talisuna, AO | 1 |
| Taylor, WR | 1 |
| Temu, EA | 1 |
| Thwing, JI | 2 |
| Tjitra, E | 2 |
| Tine, RC | 1 |
| Vaillant, MT | 1 |
| Valecha, N | 1 |
| Van den Broek, I | 1 |
| Yeka, A | 1 |
| Zongo, I | 4 |
| Sondo, P | 1 |
| Derra, K | 1 |
| Diallo-Nakanabo, S | 1 |
| Tarnagda, Z | 1 |
| Zampa, O | 1 |
| Kazienga, A | 1 |
| Valea, I | 1 |
| Sorgho, H | 1 |
| Owusu-Dabo, E | 1 |
| Guiguemde, TR | 1 |
| Ndounga, M | 1 |
| Casimiro, PN | 1 |
| Koukouikila-Koussounda, F | 1 |
| Bitemo, M | 1 |
| Diassivy Matondo, B | 1 |
| Ndounga Diakou, LA | 1 |
| Basco, LK | 1 |
| Paczkowski, M | 1 |
| Mwandama, D | 1 |
| Marthey, D | 1 |
| Luka, M | 1 |
| Makuta, G | 1 |
| Sande, J | 1 |
| Ali, D | 1 |
| Troell, P | 1 |
| Mathanga, DP | 1 |
| Gutman, J | 1 |
| Siqueira, AM | 1 |
| Alencar, AC | 1 |
| Melo, GC | 1 |
| Magalhaes, BL | 1 |
| Machado, K | 1 |
| Alencar Filho, AC | 1 |
| Kuehn, A | 1 |
| Marques, MM | 1 |
| Manso, MC | 1 |
| Felger, I | 1 |
| Vieira, JL | 1 |
| Daniel-Ribeiro, CT | 1 |
| Lacerda, MV | 1 |
| Plucinski, MM | 1 |
| Dimbu, PR | 1 |
| Macaia, AP | 1 |
| Ferreira, CM | 1 |
| Samutondo, C | 1 |
| Quivinja, J | 1 |
| Afonso, M | 1 |
| Kiniffo, R | 1 |
| Mbounga, E | 1 |
| Kelley, JS | 1 |
| Patel, DS | 1 |
| He, Y | 1 |
| Talundzic, E | 1 |
| Garrett, DO | 1 |
| Ringwald, P | 1 |
| Fortes, F | 1 |
| Ratcliff, A | 1 |
| Siswantoro, H | 1 |
| Kenangalem, E | 1 |
| Wuwung, RM | 1 |
| Purba, HL | 1 |
| Piera, KA | 1 |
| Chalfien, F | 1 |
| Marfurt, J | 1 |
| Penttinen, PM | 1 |
| Russell, B | 1 |
| Anstey, NM | 1 |
| Sowunmi, A | 3 |
| Balogun, ST | 1 |
| Gbotosho, GO | 1 |
| Happi, CT | 1 |
| Odero, CO | 1 |
| Odhiambo, FO | 1 |
| Otieno, KO | 1 |
| Kariuki, S | 1 |
| Ord, R | 1 |
| McMorrow, M | 1 |
| Vulule, J | 1 |
| Slutsker, L | 1 |
| Newman, RD | 1 |
| Hamel, MJ | 1 |
| Somé, AF | 1 |
| Séré, YY | 1 |
| Dokomajilar, C | 3 |
| Rouamba, N | 2 |
| Greenhouse, B | 1 |
| Gueye, A | 1 |
| Tine, R | 1 |
| Ndiaye, D | 1 |
| Tchania, C | 1 |
| Ndiaye, I | 1 |
| Barry, A | 1 |
| Cissé, B | 1 |
| Sutanto, I | 1 |
| Suprianto, S | 1 |
| Widiaty, A | 1 |
| Ruckert, P | 1 |
| von Bethmann, A | 1 |
| de Monbrison, F | 1 |
| Picot, S | 1 |
| Laihad, F | 1 |
| Baird, JK | 1 |
| Cattamanchi, A | 1 |
| Kyabayinze, D | 1 |
| Hubbard, A | 1 |
| LOVE, J | 1 |
| FOULK, R | 1 |
| WILLIAMS, RG | 1 |
| MITCHELL, RB | 1 |
| Lankoande, ZM | 1 |
| Lemnge, M | 1 |
| Alifrangis, M | 1 |
| Kafuye, MY | 1 |
| Segeja, MD | 1 |
| Gesase, S | 1 |
| Minja, D | 1 |
| Massaga, JJ | 1 |
| Rønn, AM | 1 |
| Bygbjerg, IC | 1 |
| Holmgren, G | 1 |
| Gil, JP | 1 |
| Morrow, RH | 1 |
| Guiguemde, RT | 1 |
| Watkins, WM | 1 |
| Sixsmith, DG | 1 |
| Spencer, HC | 1 |
| Boriga, DA | 1 |
| Kariuki, DM | 1 |
| Kipingor, T | 1 |
| Koech, DK | 1 |
| al-Yaman, F | 1 |
| Genton, B | 1 |
| Mokela, D | 1 |
| Narara, A | 2 |
| Raiko, A | 1 |
| Alpers, MP | 1 |
| Domarle, O | 1 |
| Migot-Nabias, F | 1 |
| Mvoukani, JL | 1 |
| Lu, CY | 1 |
| Nabias, R | 1 |
| Mayombo, J | 1 |
| Tiga, H | 1 |
| Sapak, P | 1 |
| Garner, P | 1 |
| Baea, M | 1 |
| Heywood, P | 1 |
| Alpers, M | 1 |
| Glew, RH | 1 |
| Miller, LH | 1 |
| Collins, WE | 1 |
| Howard, WA | 1 |
| Wyler, DJ | 1 |
| Chaves-Carballo, E | 1 |
| Neva, FA | 1 |
| Weise, HJ | 1 |
| Troidl, H | 1 |
| Lorenz, W | 1 |
| Barth, H | 1 |
| Seidel, W | 1 |
| Rohde, H | 1 |
| Goecke, K | 1 |
| Schmal, A | 1 |
| Hamelmann, H | 1 |
| Bruce-Chwatt, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and [NCT03355664] | Phase 3 | 310 participants (Actual) | Interventional | 2018-03-19 | Completed | ||
| A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains[NCT01374581] | Phase 3 | 2,117 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Pharmacovigilance for Artemisinin-based Combination Treatments in Africa[NCT01232530] | 3,176 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| A Randomised Comparative Study to Assess the Efficacy and Tolerability of Blood Schizonticidal Treatments With Artesunate Amodiaquine Winthrop® / Coarsucam (ASAQ) Versus Chloroquine (CQ) for Uncomplicated Plasmodium Vivax Monoinfection Malaria[NCT01378286] | Phase 3 | 380 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal[NCT00540410] | Phase 4 | 366 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The time taken for the tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours (NCT03355664)
Timeframe: 42 day
| Intervention | Hours to fever clearance (Mean) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 18.3 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 14.9 |
Total bilirubin, Alanine transaminase, Aspartate transaminase, Alkaline phosphatase and creatinine will be measured (NCT03355664)
Timeframe: 42 day
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 53 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 63 |
We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. (NCT03355664)
Timeframe: 28 day
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 |
"All numerators in AE tables mean that the AE was reported as present according to the definitions defined in the US government DAIDS 2017 grading tables for reporting of adverse events. The AEs are reported without grading in this table, but are graded in the paper reporting this clinical trial.~All Primary analyses are reported (also in the accepted manuscript) along with the secondary outcomes needed to support the primary analysis. Secondary outcomes not involving the randomised comparison will be updated when the analyses are available. Please note that analyses of these Secondary outcomes will take time." (NCT03355664)
Timeframe: 42 days
| Intervention | Participants (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 2 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5 |
Parasite clearance half-life assessed by microscopy as primary parameter to determine parasite clearance (NCT03355664)
Timeframe: 42 day
| Intervention | Hours (Mean) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 5 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5.5 |
Efficacy is defined as participants, following initial parasite and fever clearance, not having a recrudescence of the original plasmodium infection and fever, up to 42 days of follow up. (NCT03355664)
Timeframe: 42 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 146 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 151 |
We record the number of events where the QT interval exceeds 500ms or increases by 60ms or greater. There were zero events of this at any time point in either study arm. So no further analyses are possible. (NCT03355664)
Timeframe: Hour 4, Hour 24, Hour 28, Hour 48, Hour 52, Hour 60, Hour 64, Day 7 and Day 28 and between these time points
| Intervention | Events (Number) |
|---|---|
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 |
42-day polymerase chain reaction corrected efficacy defined as adequate clinical and parasitological response (ACPR) according to site/geographic region. (NCT03355664)
Timeframe: 42 day
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| West Cambodia | East Cambodia | Vietnam | |
| Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 35 | 90 | 26 |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 32 | 91 | 23 |
3 reviews available for amodiaquine and Recrudescence
| Article | Year |
|---|---|
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.
Topics: Africa; Amodiaquine; Antimalarials; Artemisinins; Dose-Response Relationship, Drug; Drug Combination | 2015 |
Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Drug Therapy, Combina | 2016 |
[Importation of malaria into the Federal Republic of Germany including Berlin (West) in the last ten years (1963-1972)].
Topics: Africa; Age Factors; Aircraft; Amodiaquine; Antimalarials; Asia; Berlin; Chloroquine; Disease Outbre | 1974 |
14 trials available for amodiaquine and Recrudescence
| Article | Year |
|---|---|
Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2021 |
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Dru | 2022 |
Impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2013 |
Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Faso; C | 2015 |
Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisi | 2015 |
In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2016 |
Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Brazil; Child; Child, Preschool; | 2017 |
Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Arte | 2011 |
Good efficacy of artemether-lumefantrine for uncomplicated falciparum malaria in eastern Sumba, East Nusatenggara, Indonesia.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinatio | 2012 |
A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Acute Disease; Administration, Oral; Amodiaquine; Analysis of Variance; Antimalarials; Child; Child, | 2003 |
Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya.
Topics: Amodiaquine; Animals; Antimalarials; Child; Drug Resistance, Multiple; Follow-Up Studies; Gene Ampli | 2006 |
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Faso; C | 2007 |
Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya.
Topics: Adolescent; Amodiaquine; Blood; Child; Chloroquine; Drug Combinations; Drug Resistance, Microbial; F | 1984 |
A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Acute Disease; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combi | 2002 |
17 other studies available for amodiaquine and Recrudescence
| Article | Year |
|---|---|
Activation of minority-variant Plasmodium vivax hypnozoites following artesunate + amodiaquine treatment in a 23-year old man with relapsing malaria in Antananarivo, Madagascar.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Drug Combinations; Humans; Madagascar; Malaria, Viv | 2013 |
Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015.
Topics: Amodiaquine; Angola; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2017 |
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
Topics: Adolescent; Age Distribution; Amodiaquine; Animals; Antimalarials; Chloroquine; Confidence Intervals | 2009 |
Some features of primary and recrudescent amodiaquine-resistant Plasmodium falciparum infections in Nigerian children.
Topics: Acute Disease; Amodiaquine; Animals; Antimalarials; Case-Control Studies; Child; Child, Preschool; D | 2008 |
In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Drug Resista | 2009 |
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Burkina Faso; Drug Combinations; Drug Resistan | 2010 |
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp.
Topics: Amodiaquine; Animals; Antigens, Protozoan; Antimalarials; Artemisinins; Artesunate; Child, Preschool | 2003 |
Evaluation of amodiaquin (camoquin) in the treatment of relapsing vivax malaria.
Topics: Amodiaquine; Malaria; Malaria, Vivax; Recurrence | 1953 |
Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso.
Topics: Amodiaquine; Animals; Antimalarials; Burkina Faso; Dihydropteroate Synthase; Drug Combinations; Drug | 2006 |
High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, Northeastern Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Cohort Studies; Haplotypes; Hematocrit; Human | 2006 |
Antimalarial drug combinations in vastly different settings.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkin | 2007 |
Resistance of Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990-1993.
Topics: Acute Disease; Amodiaquine; Animals; Antimalarials; Case-Control Studies; Child; Child, Preschool; C | 1996 |
Factors influencing resistance to reinfection with Plasmodium falciparum.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antibodies, Protozoan; Antimalarials; Child; Child, Prescho | 1999 |
Ineffectiveness of amodiaquine against Plasmodium falciparum malaria in symptomatic young children living in an endemic malarious area of Papua New Guinea.
Topics: Age Factors; Amodiaquine; Child; Child, Preschool; Drug Resistance; Female; Humans; Infant; Malaria, | 1991 |
Response to treatment in man of multi-drug resistant Plasmodium falciparum from Panama.
Topics: Adult; Amodiaquine; Animals; Anopheles; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug | 1974 |
Studies on a mechanism of enhancement of maximum gastric secretory response: its possible importance in recurrent ulcers after surgical treatment.
Topics: Amodiaquine; Animals; Dogs; Female; Gastric Juice; Gastric Mucosa; Histamine; Histamine Antagonists; | 1972 |
The role of drugs in a malaria program.
Topics: Amodiaquine; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Humans; Malaria; Primaqui | 1972 |